Oleg Shapiro

Oleg Shapiro

Auto-generated profile, based on publicly available information

Oleg Shapiro

SUNY Upstate Medical University, Department of Urology, Syracuse, NY

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in RadioGraphics
Verified
Journal Article
Closed access
KKKatsuhiro Kobayashi
Katsuhiro Kobayashi
AGAtin Goel
Atin Goel
MCMarlon P. Coelho
Marlon P. Coelho
MPMariangeles Medina Perez
Mariangeles Medina Perez
MKMatthew Klumpp
Matthew Klumpp
MJMohammed Jawed
Mohammed Jawed
Interventional radiologists can play a pivotal role in management of early and late complications associated with ileal conduits by performing image-guided minimally invasive procedures. Since their introduction into clinical practice in the 1950s, ileal conduits have been the most common type of urinary diversion used after radical cystectomy worldwide. Although ileal conduits are...

1 January 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
SBStephen Blakely
Stephen Blakely
GBGennady Bratslavsky
Gennady Bratslavsky
OZOsama Zaytoun
Osama Zaytoun
MDMickey Daugherty
Mickey Daugherty
SLSteve K. Landas
Steve K. Landas
OSOleg Shapiro
Oleg Shapiro

1 January 2022 in Journal of Endourology
Verified
Journal Article
Closed access
DLDominic LaBella
Dominic LaBella
APAlexandr Pinkhasov
Alexandr Pinkhasov
TSThomas Sanford
Thomas Sanford
OSOleg Shapiro
Oleg Shapiro
SWScott Wiener
Scott Wiener
Background: The majority of percutaneous nephrolithotomies (PCNLs) are performed prone, whereas most preoperative CT scans are done supine. The purpose of this pilot study is to determine if there is utility of prone CT scans in preoperative planning for prone PCNL by identifying patient populations at risk for organ injury and tract length-related complications. Materials and Methods: To represent typical preoperative planning using CT, two-dimensional (2D)-axial-prone/supine percutaneous tract measurements were performed by minimizing the distance from the target calix to the posterior-lateral skin in a single axial plane. The minimum distance and organ interception rates for the 2D-axial planning scans were recorded. Results: A total of 60 CT colonography and 13 CT urography patients were included in analysis. There were 42 women and 31 men with unspecified pathology reports ranging in age from 27 to 86 years and in body mass index (BMI) from 17.1 to 49. Multiple logistic regression identified female gender and low BMI as predictors of organ interception on the left. On multiple linear regression comparing the difference in axial prone/supine lengths; BMI, gender, and age were not significant independent predictors of changes in tract length in any pole when prone vs supine. However, shorter supine tracts tended to lengthen when prone, and longer supine tracts tended to shorten. Conclusions: This pilot study has demonstrated that patients with long and short estimates of tract length in the supine position may have shorter and longer tracts, respectively, with repositioning to prone. Thus, prone CT may have benefit when anticipating exceptionally long (>15 cm) tract lengths. Prone scans also revealed more potential organ interceptions, particularly for low BMI and women in the left upper pole. In patients for whom prone CT demonstrates an organ interception, the urologist should consider an alternate target calix or ultrasound-guided percutaneous access to identify the most appropriate needle trajectory.

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAreeb Khan
Areeb Khan
Hanan GoldbergHanan Goldberg
Hanan Goldberg
RPRuben Pinkhasov
Ruben Pinkhasov
OSOleg Shapiro
Oleg Shapiro
JJJoseph M Jacob
Joseph M Jacob
GBGennady Bratslavsky
Gennady Bratslavsky
56 Background: Mental illness is a growing issue in the USA. More individuals continue to be diagnosed with illnesses such as depression and anxiety and placed on necessary medications. Studies have shown that the psychological makeup of an individual greatly impacts their health behavior and usage of preventative measures. However, there is limited research on the effect of anxiety and depression on PSA testing. This study explores the associations between the use of anxiety and depression medications and PSA testing. Methods: We used data from the National Health Interview Survey during the year 2018, and assessed responses to the question “Have you ever had a PSA test?” and “What is the number of PSA tests you had in the last 5 years?”. Responses were stratified by whether men were taking medications for anxiety, depression, both or none. We performed multivariable logistic regression analysis to define adjusted odds ratios of undergoing PSA testing adjusting for relevant socio-economic and demographic parameters. Results: Among the 5,035 male participants, 89.4% did not take any medication, 2.9% reported they took anxiety medication, 2.1% took depression medication and 5.5% took both medications. There was a significantly higher rate of PSA testing in men who took medications for both anxiety and depression compared to men taking no medications (p=0.002). Furthermore, the average number of PSA tests in the last 5 years was highest in the group of men taking both medications ( p < 0.0001). Multivariable analysis showed that men who took medications for both depression and anxiety were more likely to undergo PSA testing in comparison to men, not on any of these medications (OR=1.755, p=0.001). The multivariable analysis also showed that age, living with a spouse, and prior cancer history were associated with an increased likelihood of PSA testing while being a minority, living in the south of the USA, and being a current smoker was associated with a lower likelihood of undergoing PSA testing. Conclusions: Taking both anxiety and depression medications in men may be associated with a higher likelihood of undergoing PSA testing. Despite obvious limitations of this analysis including its retrospective nature and recall bias, this association needs to be further explored, especially due to rising use of these medication in the current era of the COVID-19 pandemic.[Table: see text]

1 October 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MHMichael Joseph Herriges
Michael Joseph Herriges
RPRuben Pinkhasov
Ruben Pinkhasov
KLKeren Lehavot
Keren Lehavot
OSOleg Shapiro
Oleg Shapiro
JJJoseph M Jacob
Joseph M Jacob
Hanan GoldbergHanan Goldberg
Hanan Goldberg
129 Background: Data on heterogeneity in cancer screening and diagnosis rates among lesbians/gays and bisexuals is lacking. Recent studies showed that lesbians/gays and bisexuals have decreased healthcare utilization compared to heterosexual counterparts and continue to experience discrimination in healthcare. Few studies have examined how sexual orientation impacts cancer screening and prevalence. We, therefore, investigated the association between sexual orientation and prevalent sex-specific cancer including prostate, breast, and cervical cancer. Methods: This was a cross-sectional survey-based US study, including men and women aged 18+ from the Health Information National Trends Survey (HINTS) database between 2017-2019. The primary endpoint was individual-reported prostate, breast, and cervical cancer screening and prevalence rates among heterosexual and LGB men and women. Multivariable logistic regression analyses assessed association of various covariates with undergoing screening and diagnosis of these cancers. Results: Overall, 4,441 and 6,333 heterosexual men and women, respectively, were compared to 225 and 213 lesbian/gay and bisexual men and women, respectively. Lesbians/gays and bisexuals were younger and less likely to be screened for prostate, breast, and cervical cancer than heterosexuals. A higher proportion of heterosexual women than lesbian and bisexual women were screened for cervical cancer with pap smears (95.36% vs. 90.48% and 86.11%, p = < 0.001) and breast cancer with mammograms (80.74% vs. 63.81% and 45.37%, p = < 0.001). Similarly, a higher proportion of heterosexual men than gay and bisexual men were screened for prostate cancer with PSA blood tests (41.27% vs. 30.53% and 27.58%, p = < 0.001). Conclusions: Lesbians/gays and bisexuals in the US may be less likely to undergo screening of sex-specific prevalent malignancies, including prostate, breast, and cervical cancer. Healthcare professionals should be encouraged to improve cancer screening among lesbians/gays and bisexuals.

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlon Ya'aqov Lazarovich
Alon Ya'aqov Lazarovich
TCThenappan Chandrasekar
Thenappan Chandrasekar
OSOleg Shapiro
Oleg Shapiro
JJJoseph M Jacob
Joseph M Jacob
ABAlina Basnet
Alina Basnet
Hanan GoldbergHanan Goldberg
Hanan Goldberg
230 Background: Prostate specific antigen (PSA) screening remains a controversial issue. However, most urological guidelines recommend PSA testing through a shared decision-making process with the patient. The rate of PSA screening in men with a history of cancer compared to men with no cancer history is not well known. We aimed to compare PSA testing in men aged 55-69 years with and without a history of cancer (excluding prostate cancer patients). Methods: Utilizing the National Health Interview Survey (NHIS) a retrospective cross-sectional study between the years 2015 and 2018 was carried out to analyze and compare PSA testing rates in men aged 55-69 years. Multivariable logistic regression model was implemented do demonstrate potential associations with PSA testing. Results: A total of 13,850 men aged 55-69 years included in the NHIS Survey were analyzed. 1519 (10.9%) men had a history of cancer (non-prostate). On multivariable analysis, men who were previously diagnosed with cancer had a higher rate of PSA testing compared to men with no history of cancer (OR: 1.88, 95% CI 1.39-2.54, p < 0.001). Other factors associated with an increased likelihood of undergoing PSA testing included: age, homosexual orientation, and married men. In contrast, current smokers, American Indians and Alaskan Natives and Asians were less likely to undergo PSA testing. Conclusions: Our data suggest that men aged 55-69 with a history of cancer are more likely to undergo PSA testing than men with no cancer history.